Long Ideas - On the back of sequestration cuts and CMS (Centers for Medicare and Medicaid Services) rate changes, another home healthcare provider has guided for a far … Continue Reading
Read NowLong Ideas - Since late last year when Orexigen (OREX) revealed that its cardiovascular outcomes trial, the LIGHT study, was enrolling faster than anticipated and that the FDA … Continue Reading
Read NowLong Ideas - As investors packed up in search of more exciting prospects, shares of OraSure Technologies (OSUR) have been slashed in half since their highs in mid-2012, … Continue Reading
Read NowLong Ideas - Although Illumina was slapped with a $96M fine by a federal jury this week, the monetary penalty isn’t all that detrimental to the $6B company; … Continue Reading
Read NowLong Ideas - On the evening of March 14, Illumina (ILMN) announced that a federal jury found it guilty of infringing a patent held by Syntrix Biosystems relating … Continue Reading
Read NowLong Ideas - Within the history of the biotechnology sector, few franchises have gone from blockbuster status to peak to decline as quickly as that of Incivek, Vertex … Continue Reading
Read NowLong Ideas - Keryx Biopharmaceuticals’ (KERX) CEO, Ron Bentsur, spent much of the company’s 4Q/YE12 earnings conference call reviewing patents, pending patents, and potential exclusivity designations for Zerenex, … Continue Reading
Read Now